NCT02107105 Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer
| NCT ID | NCT02107105 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Rectal Adenocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 430 participants |
| Start Date | 2014-05-16 |
| Primary Completion | 2030-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 430 participants in total. It began in 2014-05-16 with a primary completion date of 2030-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates quality of life and utilities following surgical treatment of stage I-IV rectal cancer. This study may help researches learn more about quality of life in patients who have or have had rectal cancer.
Eligibility Criteria
Inclusion Criteria: * Patient has histologically proven adenocarcinoma of the rectum (stage I - IV) that is planned to be treated by surgical resection performed with curative intent, or who has already received surgical treatment * Patient must sign an approved informed consent document and have the literary and physical ability to complete the questionnaire in English Exclusion Criteria: * Patient has been treated with pelvic radiation therapy for a diagnosis other than rectal cancer * Patient has a concurrent cancer diagnosis at the time of consent * Patient has recurrent disease
Contact & Investigator
George J Chang
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT02107105 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rectal Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02107105 currently recruiting?
Yes, NCT02107105 is actively recruiting participants. Contact the research team at GChang@mdanderson.org for enrollment information.
Where is the NCT02107105 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT02107105 clinical trial?
NCT02107105 is sponsored by M.D. Anderson Cancer Center. The principal investigator is George J Chang at M.D. Anderson Cancer Center. The trial plans to enroll 430 participants.